|

[18F]PSMA-1007 Clinical Trials

2 actively recruiting trials

Pipeline

Phase 3: 2

Top Sponsors

  • University of Alberta1
  • ABX advanced biochemical compounds GmbH1

Indications

  • Prostate Cancer2
  • Cancer2

Other2 trials

18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028
Phase 3
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.